Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mazdutide for Remission of Type 2 Diabetes
NCT07767552Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Mazdutide 6 mg with placebo (2 arms). Primary endpoint: Normal Glucose Regulation at 44 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mazdutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07767552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07767552.